- Record: found
- Abstract: found
- Article: found
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Eric R Siemers
1 ,
Karen L Sundell
2 ,
Christopher Carlson
2 ,
Michael Case
2 ,
Gopalan Sethuraman
2 ,
Hong Liu-Seifert
2 ,
Sherie A Dowsett
2 ,
Michael J Pontecorvo
3 ,
Robert A Dean
2 ,
Ronald Demattos
2
Feb 2016
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
EXPEDITION and EXPEDITION2 were identically designed placebo-controlled phase 3 studies assessing effects of solanezumab, an antiamyloid monoclonal antibody binding soluble amyloid-β peptide, on cognitive and functional decline over 80 weeks in patients with mild-to-moderate Alzheimer's disease (AD). Primary findings for both studies have been published.